Last $7.72 USD
Change Today -0.03 / -0.39%
Volume 27.1K
ARGS On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

argos therapeutics inc (ARGS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - $13.74
52 Week Low
07/29/14 - $5.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

argos therapeutics inc (ARGS) Related Businessweek News

No Related Businessweek News Found

argos therapeutics inc (ARGS) Details

Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its products include AGS-003, which is under Phase III clinical trials and intended for the treatment of metastatic renal cell carcinoma (clear cell); and AGS-004, which is under Phase IIb clinical trials and is intended for the treatment of Human Immunodeficiency Virus. The company also develops AGS-003 for metastatic renal cell carcinoma (non-clear cell), early stage RCC, and other solid tumors. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.

92 Employees
Last Reported Date: 03/31/14
Founded in 1997

argos therapeutics inc (ARGS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $436.8K
Chief Operating officer and Vice President of...
Total Annual Compensation: $335.9K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: $321.3K
Compensation as of Fiscal Year 2013.

argos therapeutics inc (ARGS) Key Developments

Argos Therapeutics, Inc. - Special Call

To discuss the AGS-004 Phase 2b results and to provide update on clinical research for Investigational Fully Personalized Immunotherapy for the treatment of HIV

Argos Therapeutics, Inc. Provides Update on Clinical Research Program for AGS-004

Argos Therapeutics Inc. provided an update on its clinical research program for AGS-004, the company's investigational fully personalized immunotherapy for the treatment of HIV. The company announced top-line results of its double-blind, placebo-controlled Phase 2b clinical trial of AGS-004 in patients chronically infected with HIV-1. The primary endpoint of the trial, which required a 1.1 Log lower median viral load (VL) after 12 weeks of interruption of antiretroviral therapy (ATI) in the treatment group versus the placebo group, was not achieved. Importantly, however, data from the trial provided evidence of the ability of AGS-004 to induce memory T-cell responses which may have directly impacted the latent viral reservoir. Of the patients who received AGS-004 and completed ATI, approximately 70% had positive antiviral memory T-cell responses prior to ATI versus 0% of placebo patients. Also, within the AGS-004 treatment group, those patients that had antiviral memory T-cell responses had significantly fewer CD4+ T-cells with integrated HIV DNA when compared to non-responders. These findings relate directly to the utilization of AGS-004 in an ongoing adult eradication study and a planned pediatric study, where one of the key objectives is to decrease the latent HIV reservoir. In the Phase 2b trial, 54 patients received four doses of AGS-004 or placebo every four weeks while on standard antiretroviral therapy (ART), and then began a 12-week ATI, during which dosing continued every four weeks. In total, 36 participants completed ATI, 23 of whom received AGS-004. The trial was fully funded by NIAID, NIH.

Argos Therapeutics Inc. and Saint-Gobain Announce Collaboration Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies

Argos Therapeutics Inc. announced a collaboration with Saint-Gobain's Performance Plastics division. Under the terms of the agreement, Saint-Gobain will partner with Argos to design, integrate and scale production of a range of disposables for use in the automated manufacturing of Argos' lead product candidate, AGS-003, currently being tested in a Phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARGS:US $7.72 USD -0.03

ARGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARGS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ARGS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARGOS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at